Can Omeprazole IV Cause Hyponatremia?
Yes, intravenous omeprazole can cause hyponatremia, though the FDA label does not explicitly list hyponatremia as a recognized adverse effect. However, the mechanism appears to be syndrome of inappropriate antidiuretic hormone secretion (SIADH), and the risk is highest within the first few weeks of initiating therapy 1.
Evidence from FDA Labeling
The official FDA labeling for omeprazole IV does not include hyponatremia as a listed adverse reaction or warning 1. The label does warn about hypomagnesemia (which can secondarily lead to hypokalemia), but hyponatremia is notably absent from the documented electrolyte disturbances.
Evidence from Clinical Research
Despite the absence in FDA labeling, robust clinical evidence demonstrates a clear association between omeprazole and hyponatremia:
Time-Course and Risk Profile
Newly initiated PPI therapy carries the highest risk: The adjusted odds ratio for hospitalization due to hyponatremia with newly initiated omeprazole (≤90 days) is 2.67 (95% CI 2.37-3.01) 2.
Risk is most pronounced in the first week: A 2023 study showed the risk peaks immediately after initiation with an adjusted OR of 6.87 (95% CI 4.83-9.86) in the first week, then gradually declines to an OR of 1.64 by week five 3.
Ongoing treatment shows minimal risk: For patients on long-term omeprazole therapy, the adjusted OR drops to 1.04 (0.97-1.11), suggesting hyponatremia is primarily a concern with recent initiation 2.
Clinical Mechanism
The mechanism is SIADH, which has been documented in multiple case reports 4, 5. One case demonstrated sequential hyponatremia with both omeprazole and pantoprazole, suggesting this may be a class effect of PPIs rather than specific to omeprazole alone 5.
Clinical Approach
When to Suspect PPI-Induced Hyponatremia
Consider omeprazole as the culprit when:
- Hyponatremia develops within days to weeks of starting therapy 3, 4
- Patient presents with euvolemic hyponatremia
- Laboratory findings show: low serum osmolality (<280 mOsm/L), elevated urine osmolality (>100 mOsm/kg), and urine sodium >30 mmol/L 5
- Other common causes (thiazides, SSRIs, antiepileptics) have been excluded
Management Algorithm
Discontinue omeprazole immediately when PPI-induced hyponatremia is suspected 4, 5
Do NOT switch to another PPI - case reports demonstrate cross-reactivity between different PPIs, suggesting a class effect 5
Consider alternative acid suppression: Switch to H2-receptor antagonists (e.g., ranitidine, famotidine) if ongoing acid suppression is needed 5
Monitor sodium levels closely: Expect normalization within days to weeks after discontinuation 4, 5
If another PPI must be used (after careful consideration), monitor serum sodium concentrations closely 5
Critical Caveats
Important pitfall: If a patient has been on omeprazole for months to years without issue, it is a less likely cause of new-onset hyponatremia 3. In such cases, investigate other etiologies more aggressively.
Severity can be profound: Case reports document severe symptomatic hyponatremia (sodium as low as 127 mmol/L) developing rapidly, even with brief exposure 6, 4, 5. One case resulted in acute disseminated encephalomyelitis (ADEM) 4.
Route of administration: While the question specifically asks about IV omeprazole, the research evidence predominantly involves oral formulations. However, the mechanism (SIADH) would apply regardless of route, and IV administration may theoretically pose similar or greater risk given potentially higher initial drug levels.